148 related articles for article (PubMed ID: 11956608)
1. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
Würl P; Bartel F; Meye A; Kappler M; Bache M; Schmidt H; Schönfelder M; Taubert H
Int J Oncol; 2002 May; 20(5):1087-93. PubMed ID: 11956608
[TBL] [Abstract][Full Text] [Related]
2. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene.
Meye A; Würl P; Bache M; Bartel F; Grünbaum U; Mansa-ard J; Schmidt H; Taubert H
Cancer Lett; 2000 Feb; 149(1-2):181-8. PubMed ID: 10737722
[TBL] [Abstract][Full Text] [Related]
3. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
Grünbaum U; Meye A; Bache M; Bartel F; Würl P; Schmidt H; Dunst J; Taubert H
Anticancer Res; 2001; 21(3B):2065-71. PubMed ID: 11497299
[TBL] [Abstract][Full Text] [Related]
4. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
5. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
6. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
Prasad G; Wang H; Agrawal S; Zhang R
Anticancer Res; 2002; 22(1A):107-16. PubMed ID: 12017271
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
8. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
Mu Z; Hachem P; Agrawal S; Pollack A
Prostate; 2004 Aug; 60(3):187-96. PubMed ID: 15176048
[TBL] [Abstract][Full Text] [Related]
9. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
13. Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts.
Green DW; Roh H; Pippin JA; Drebin JA
J Surg Res; 2001 Nov; 101(1):16-20. PubMed ID: 11676549
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitization by antisense oligonucleotides targeting MDM2.
Bianco R; Ciardiello F; Tortora G
Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
Chen L; Agrawal S; Zhou W; Zhang R; Chen J
Proc Natl Acad Sci U S A; 1998 Jan; 95(1):195-200. PubMed ID: 9419352
[TBL] [Abstract][Full Text] [Related]
17. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
Zhang R; Wang H; Agrawal S
Curr Cancer Drug Targets; 2005 Feb; 5(1):43-9. PubMed ID: 15720188
[TBL] [Abstract][Full Text] [Related]
18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
19. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation.
Mahdi T; Alcalay D; Cognard C; Tanzer J; Kitzis A
Biol Cell; 1998 Dec; 90(9):615-27. PubMed ID: 10085538
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells.
Beech D; Pollock RE; Tsan R; Radinsky R
Int J Oncol; 1998 Feb; 12(2):329-36. PubMed ID: 9458358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
